Skip navigation

Pfizer-Wyeth Merger Rolls Forward; Meetings Casualties Still Uncertain

Pfizer completed its $67 billion acquisition of one-time-competitor Wyeth Pharmaceuticals on October 15, just one in a string of recent mergers and acquisitions in the pharmaceutical industry. (Think Merck’s November 3 merger with Schering-Plough and Genentech’s March 26 deal with Roche.) According to a variety of sources, plans are already in place to merge the companies’ meetings teams, but Pfizer representatives are staying very close-lipped about the process, and so far, there are more

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.